<?xml version="1.0" ?>
<document id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a">
  <chunk id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c0" text="Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4">
    <entity charOffset="34-42" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c0.e0" ontology_id="CHEBI_16670" text="Peptides" type="chemical"/>
    <entity charOffset="79-86" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c0.e1" ontology_id="CHEBI_16541" text="Protein" type="chemical"/>
  </chunk>
  <chunk id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1" text="The Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 and caused continual outbreaks worldwide with high mortality. However, no effective anti-MERS-CoV drug is currently available. Recently, numerous evolutionary studies have suggested that MERS-CoV originated from bat coronavirus (BatCoV). We herein reported that three peptides derived from the HR2 region in spike protein of BatCoV HKU4, including HKU4-HR2P1, HKU4-HR2P2 and HKU4-HR2P3, could bind the MERS-CoV HR1-derived peptide to form a six-helix bundle (6-HB) with high stability. Moreover, these peptides, particularly HKU4-HR2P2 and HKU4-HR2P3, exhibited potent inhibitory activity against MERS-CoV S-mediated cell-cell fusion and viral infection, suggesting that these HKU4 HR2-derived peptides could be candidates for futher development as antiviral agents against MERS-CoV infection.">
    <entity charOffset="4-36" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e0" ontology_id="DOID_0080642" text="Middle East respiratory syndrome" type="disease"/>
    <entity charOffset="28-36" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e1" ontology_id="DOID_225" text="syndrome" type="disease"/>
    <entity charOffset="174-178" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e2" ontology_id="CHEBI_23888" text="drug" type="chemical"/>
    <entity charOffset="344-352" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e3" ontology_id="CHEBI_16670" text="peptides" type="chemical"/>
    <entity charOffset="390-397" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e4" ontology_id="CHEBI_16541" text="protein" type="chemical"/>
    <entity charOffset="499-506" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e5" ontology_id="CHEBI_16670" text="peptide" type="chemical"/>
    <entity charOffset="578-586" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e6" ontology_id="CHEBI_16670" text="peptides" type="chemical"/>
    <entity charOffset="770-778" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e7" ontology_id="CHEBI_16670" text="peptides" type="chemical"/>
    <entity charOffset="825-834" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e8" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="825-841" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e9" ontology_id="CHEBI_22587" text="antiviral agents" type="chemical"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e0" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e2" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.p0" relation="true"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e0" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e3" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.p1" relation="true"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e0" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e4" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.p2" relation="true"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e0" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e5" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.p3" relation="true"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e0" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e6" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.p4" relation="true"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e0" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e7" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.p5" relation="true"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e0" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e8" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.p6" relation="true"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e0" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e9" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.p7" relation="true"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e1" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e2" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.p8" relation="true"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e1" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e3" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.p9" relation="true"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e1" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e4" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.p10" relation="true"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e1" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e5" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.p11" relation="true"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e1" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e6" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.p12" relation="true"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e1" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e7" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.p13" relation="true"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e1" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e8" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.p14" relation="true"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e1" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.e9" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c1.p15" relation="true"/>
  </chunk>
  <chunk id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2" text="Viruses 2019, 11, 56 2 of 12 displays its spike protein (S), a type I transmembrane glycoprotein, on its enveloped membrane surface in a trimer state. S protein contains two subunits: S1 subunit (S1) and S2 subunit (S2). S1 recognizes and binds the cellular receptor, while S2 mediates viral and cellular membrane fusion. The interaction between the receptor-binding domain (RBD) in S1 and the receptor (DPP4) on the host cell surface induces S2 structural changes, including the insertion of N-terminal fusion peptide into the host cell membrane, the formation of a homotrimer by heptad repeat 1 (HR1) helices, exposing three hydrophobic grooves on the surface, and the binding of three heptad repeat 2 (HR2) molecules to the hydrophobic grooves of HR1 trimer to form a six-helix bundle (6-HB), which brings the viral and cell membranes close together for fusion. Finally, MERS-CoV releases its genetic materials into target cells ( Figure 1B) [11, 12] . Disrupting the process of MERS-6HB formation can inhibit virus-cell membrane fusion and abolish viral infection [13, 14] . Our previous studies found that a peptide, MERS-HR2P, derived from the MERS-CoV HR2 region, could prevent the formation of the fusion core by competitively binding to HR1 and blocking the native interaction between HR1 and HR2 ( Figure 1B) . MERS-HR2P has no effect on SARS-CoV infection, and SARS-CoV HR2-derived peptide, CP-1, failed to inhibit MERS-CoV infection [14, 15] , suggesting that MERS-HR2P is specific for inibiting MERS-CoV infection. Whether other novel and potent peptide fusion inhibitors can be developed against MERS-CoV from other coronavirus HR2 regions is still unclear.">
    <entity charOffset="48-55" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e0" ontology_id="CHEBI_16541" text="protein" type="chemical"/>
    <entity charOffset="153-160" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e1" ontology_id="CHEBI_16541" text="protein" type="chemical"/>
    <entity charOffset="511-518" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e2" ontology_id="CHEBI_16670" text="peptide" type="chemical"/>
    <entity charOffset="710-719" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e3" ontology_id="CHEBI_25367" text="molecules" type="chemical"/>
    <entity charOffset="1052-1067" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e4" ontology_id="DOID_934" text="viral infection" type="disease"/>
    <entity charOffset="1113-1120" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e5" ontology_id="CHEBI_16670" text="peptide" type="chemical"/>
    <entity charOffset="1393-1400" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e6" ontology_id="CHEBI_16670" text="peptide" type="chemical"/>
    <entity charOffset="1559-1566" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e7" ontology_id="CHEBI_16670" text="peptide" type="chemical"/>
    <entity charOffset="1574-1584" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e8" ontology_id="CHEBI_35222" text="inhibitors" type="chemical"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e0" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e4" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.p0" relation="true"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e1" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e4" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.p1" relation="true"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e2" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e4" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.p2" relation="true"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e3" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e4" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.p3" relation="true"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e4" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e5" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.p4" relation="true"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e4" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e6" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.p5" relation="true"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e4" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e7" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.p6" relation="true"/>
    <pair e1="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e4" e2="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.e8" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c2.p7" relation="true"/>
  </chunk>
  <chunk id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c3" text="Although camels are the intermediate host for the transmission of MERS-CoV, bats are likely to be its original source and serve as the natural host [10, [16] [17] [18] . Phylogenetically, MERS-CoV is very closely related to Tylonycteris sp. Bat CoV HKU4 (Ty-BatCoV HKU4) ( Figure 1A ). Similar to MERS-CoV, HKU4 also harbors the ability to use human DPP4 as the receptor for infecting the target cell [19, 20] . We herein identified that HKU4-HR2P1, HKU4-HR2P2 and HKU4-HR2P3 peptides, derived from the HKU4 HR2 region, could bind MERS-HR1P, a MERS-CoV HR1-derived peptide, and mimic the interaction of MERS-CoV HR1 and HR2 regions to form stable 6-HB. Moreover, these peptides exhibited significant inhibitory activity in both MERS-CoV S-mediated cell-cell fusion assay and pseudovirus infection assay, with even more potency than that of the reported peptide, MERS-HR2P. Taken together, these HKU4 HR2-derived peptides could be considered as candidates for the development of anti-MERS-CoV agents for clinical use.">
    <entity charOffset="476-484" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c3.e0" ontology_id="CHEBI_16670" text="peptides" type="chemical"/>
    <entity charOffset="669-677" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c3.e1" ontology_id="CHEBI_16670" text="peptides" type="chemical"/>
    <entity charOffset="912-920" id="e68b0f3da8a02a8f0b86869e533eaf549f70ff9a.c3.e2" ontology_id="CHEBI_16670" text="peptides" type="chemical"/>
  </chunk>
</document>
